Iktos Announces Research Collaboration with Janssen to Utilize Iktos’ Artificial Intelligence Technology to Increase Speed & Efficiency of Small Molecule Drug Discovery

PARIS–(BUSINESS WIRE)–Iktos, a company specializing in Artificial Intelligence (AI)
technologies applied to new drug design, announced today the initiation
of a collaboration agreement with Janssen Pharmaceutica NV. As part of
the collaboration, Iktos virtual drug design technology will be
implemented and applied to several Janssen small molecule drug discovery
projects. Iktos will collaborate with Janssen to develop new
applications, leveraging Iktos’ proprietary know-how in deep generative
models applied to chemistry and Janssen expertise in AI-enabled
prediction of small molecule activities.

Building on deep generative models, Iktos is developing a proprietary
and innovative technology for in silico drug design which has the
potential to enable vast improvements in drug discovery workflows, based
on its unique capacity to explore chemical space with speed and
efficiency, thus enabling identification of molecules that meet the
desired criteria in a given research project.

“We are thrilled to be able to announce a strategic collaboration with
Janssen, one of the largest pharma companies in the world, and highly
respected for the quality of their science and their visionary
perspective regarding the use of big data and machine learning to
progress pharma R&D efficiency,” commented Yann Gaston-Mathé, CEO of
Iktos. “It is a major recognition for Iktos to be selected by Janssen as
a partner for implementation and development of generative modeling
technology for new drug design. Iktos has been a pioneer in the
application of generative models for drug discovery and is emerging as a
world leader in a technology that has the potential to disrupt the way
new therapeutics are designed.”

Iktos has recently announced collaborations with several
biopharmaceutical companies where Iktos AI technology is used to
accelerate the design of promising compounds, and has published, at the
EFMC 2018 meeting, an experimental validation of the technology in a
real-life drug discovery project. Iktos is planning to release its SaaS
software, Makya™, as a beta version available for testing by customers,
by mid-2019.

About Iktos

Incorporated in October 2016, Iktos is a French start-up company
specializing in the development of artificial intelligence solutions
applied to chemical research, more specifically medicinal chemistry and
new drug design. Iktos is developing a proprietary and innovative
solution based on deep learning generative models, which enables the use
of existing data to design molecules that are optimized in silico
to meet the success criteria of a small molecule discovery project. The
use of Iktos technology enables major productivity gains in upstream
pharmaceutical R&D. Iktos offers its technology to its customers both as
professional services and as a SaaS software platform, Makya™.
More
information on: www.iktos.ai

Contacts

Yann Gaston-Mathé (CEO)
[email protected]
+33
6 30 07 99 26